Search - tctmd.com

Displaying 1 - 20 of 149

Sort: Relevancy | Date

Presentation Miami Valves 2023

What’s New In Renal Denervation?

Presenter: Sergio Perez

February 04, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

Presentation ACC 2019

Chemical Renal Denervation with Alcohol: The Post-Market Study Data and The Target BP Program

Presenter: Horst Sievert

March 18, 2019

Presentation CDM 2018

The Hope and Promise of Renal Denervation

Presenter: Michael A.Weber

October 12, 2018

Presentation

Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Effect of Renal Denervation

Presenter: James P. Howard

January 11, 2016

Presentation CCVVC 2015

New Concepts in Endovascular Treatment: Present And Future Status Of Renal Denervation After The Negative SIMPLICITY Trial

Presenter: Mark Wholey

June 17, 2015

Presentation ISET 2015

Is There Hope for Renal Denervation?

Presenter: Ron Waksman

February 01, 2015

Presentation ISET 2015

Current Challenge and Directions in Renal Denervation

Presenter: Marty B. Leon

February 01, 2015

Presentation

Randomized Comparison of Renal Denervation vs Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension

Presenter: J?n Rosa

December 04, 2014

Presentation TCT 2014

Noninvasive Renal Denervation Using Externally Delivered Focused Ultrasound: Early Experience Using Doppler-Based Imaging Tracking and Targeting for Treatment

Presenter: Michael Joner, Horst Sievert, Steven L. Almany, John A. Ormiston

September 16, 2014

Presentation TCT 2014

What Is the Clinical Trial Pathway Moving Forward for Renal Denervation?

Presenter: Ajay J. Kirtane, Bram D. Zuckerman, Paul A. Sobotka

September 16, 2014

Presentation TCT 2014

Global Perspectives in the Post-HTN-3 Era: A Kinder and Gentler Interpretation of Renal Denervation Therapy

Presenter: Ajay J. Kirtane, Bram D. Zuckerman, Paul A. Sobotka, Felix Mahfoud

September 16, 2014

Presentation TCT 2014

New Insights from SYMPLICITY HTN-3 What I Learned and What I Would Have Done Differently

Presenter: Ajay J. Kirtane, Bram D. Zuckerman, Paul A. Sobotka, Deepak L. Bhatt

September 16, 2014

$Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Mild Refractory Hypertension$

Presentation TCT 2014

Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Mild Refractory Hypertension

Presenter: Ajay J. Kirtane, Deepak L. Bhatt, Steffen Desch

September 16, 2014

Presentation TCT 2014

CON Problematic and Challenged

Presenter: Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

PRO Continued Optimism

Presenter: Felix Mahfoud

September 16, 2014

Presentation TCT 2014

Unfavourable Anatomy Of Renal Arteries Should Not Be An Exclusion Criteria For Renal Sympathetic Denervation

Presenter: Alexander Plehn

September 16, 2014

Presentation TCT 2014

Second generation devices for renal denervation give better renal blood flow when compared with 1st generation catheters

Presenter: Waleed Kadro

September 16, 2014

Advertisement

What’s New In Renal Denervation?

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Current Status and Future of Renal Denervation for Hypertension

Chemical Renal Denervation with Alcohol: The Post-Market Study Data and The Target BP Program

The Hope and Promise of Renal Denervation

Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Effect of Renal Denervation

New Concepts in Endovascular Treatment: Present And Future Status Of Renal Denervation After The Negative SIMPLICITY Trial

Is There Hope for Renal Denervation?

Current Challenge and Directions in Renal Denervation

Randomized Comparison of Renal Denervation vs Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension

Noninvasive Renal Denervation Using Externally Delivered Focused Ultrasound: Early Experience Using Doppler-Based Imaging Tracking and Targeting for Treatment

What Is the Clinical Trial Pathway Moving Forward for Renal Denervation?

Global Perspectives in the Post-HTN-3 Era: A Kinder and Gentler Interpretation of Renal Denervation Therapy

New Insights from SYMPLICITY HTN-3 What I Learned and What I Would Have Done Differently

Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Mild Refractory Hypertension

CON Problematic and Challenged

PRO Continued Optimism

Unfavourable Anatomy Of Renal Arteries Should Not Be An Exclusion Criteria For Renal Sympathetic Denervation

Second generation devices for renal denervation give better renal blood flow when compared with 1st generation catheters

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content